Circulating acetaminophen metabolites are toxicokinetic biomarkers of acute liver injury

Clinical Pharmacology and Therapeutics

Volumn 101, Issue 4, 2017, Pages 531-540

  Vliegenthart, A D B ^a   Kimmitt, R A ^a   Seymour, J H ^a   Homer, N Z ^a   Clarke, J I ^b   Eddleston, M ^a   Gray, A ^c   Wood, D M ^d,e   Dargan, P I ^d,e   Cooper, J G ^f   Antoine, D J ^b   Webb, D J ^a   Lewis, S C ^g   Bateman, D N ^a   Dear, J W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CYTOCHROME P450; ONDANSETRON; PARACETAMOL; PLACEBO; ANALGESIC AGENT; ANTIEMETIC AGENT; SCAVENGER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLITE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TOXIC HEPATITIS; TOXICOKINETICS; VALIDATION STUDY; BLOOD; DRUG INTERACTION; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; YOUNG ADULT;

ACETAMINOPHEN; ACETYLCYSTEINE; ADULT; ALANINE TRANSAMINASE; ANALGESICS, NON-NARCOTIC; ANTIEMETICS; AREA UNDER CURVE; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG OVERDOSE; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; REPRODUCIBILITY OF RESULTS; ROC CURVE; TOXICOKINETICS; YOUNG ADULT;

EID: 85006508376     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.541     Document Type: Article

References (37)

1. Larson, A.M. et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42, 1364–1372 (2005).
2. Altyar, A., Kordi, L. & Skrepnek, G. Clinical and economic characteristics of emergency department visits due to acetaminophen toxicity in the USA. BMJ Open 5, e007368 (2015).
3. Bateman, D.N. et al. Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment. Br. J. Clin. Pharmacol. 78, 610–618 (2014).
4. Hawton, K. et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 346, f403 (2013).
5. Antoine, D.J. et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 58, 777–787 (2013).
6. Prescott, L.F. Kinetics and metabolism of paracetamol and phenacetin. Br. J. Clin. Pharmacol. 10(suppl. 2), 291s–298s (1980).
7. Xie, Y. et al. Time course of acetaminophen-protein adducts and acetaminophen metabolites in circulation of overdose patients and in HepaRG cells. Xenobiotica 45, 921–929 (2015).
8. Prescott, L.F., Critchley, J.A., Balali-Mood, M. & Pentland, B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br. J. Clin. Pharmacol. 12, 149–153 (1981).
9. Lau, G.S. & Critchley, J.A. The estimation of paracetamol and its major metabolites in both plasma and urine by a single high-performance liquid chromatography assay. J. Pharm. Biomed. Anal. 12, 1563–1572 (1994).
10. Heitmeier, S. & Blaschke, G. Direct determination of paracetamol and its metabolites in urine and serum by capillary electrophoresis with ultraviolet and mass spectrometric detection. J. Chromatogr. B Biomed. Sci. Appl. 721, 93–108 (1999).
11. Winnike, J.H., Li, Z., Wright, F.A., Macdonald, J.M., O'Connell, T.M. & Watkins, P.B. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88, 45–51 (2010).
12. Muldrew, K.L. et al. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab. Dispos. 30, 446–451 (2002).
13. Davern, T.J., 2nd et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 130, 687–694 (2006).
14. James, L. et al. Comparison of bile acids and acetaminophen protein adducts in children and adolescents with acetaminophen toxicity. PLoS One 10, e0131010 (2015).
15. James, L.P. et al. Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab. Dispos. 37, 1779–1784 (2009).
16. McGill, M.R. et al. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol. Appl. Pharmacol. 269, 240–249 (2013).
17. Smilkstein, M.J., Knapp, G.L., Kulig, K.W. & Rumack, B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Med. 319, 1557–1562 (1988).
18. Prescott, L.F., Park, J., Ballantyne, A., Adriaenssens, P. & Proudfoot, A.T. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 2, 432–434 (1977).
19. Lauterburg, B.H., Corcoran, G.B. & Mitchell, J.R. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J. Clin. Investig. 71, 980–991 (1983).
20. Bateman, D.N. Paracetamol poisoning: beyond the nomogram. Br. J. Clin. Pharmacol. 80, 45–50 (2015).
21. Stutchfield, B.M. et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology 149, 1896–1909 (2015).
22. Huebener, P. et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J. Clin. Invest. 125, 539–550 (2015).
23. Dear, J.W. & Antoine, D.J. Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges. Expert Rev. Clin. Pharmacol. 7, 181–189 (2014).
24. Bateman, D.N. et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 383, 697–704 (2014).
25. Whyte, I.M., Buckley, N.A., Reith, D.M., Goodhew, I., Seldon, M. & Dawson, A.H. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther. Drug Monit. 22, 742–748 (2000).
26. Clements, J.A., Critchley, J.A. & Prescott, L.F. The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br. J. Clin. Pharmacol. 18, 481–485 (1984).
27. Gelotte, C.K., Auiler, J.F., Lynch, J.M., Temple, A.R. & Slattery, J.T. Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin. Pharmacol. Ther. 81, 840–848 (2007).
28. Zaher, H. et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol. Appl. Pharmacol. 152, 193–199 (1998).
29. Gonzalez, F.J. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab. Dispos. 35, 1–8 (2007).
30. Mitchell, J.R., Jollow, D.J., Potter, W.Z., Davis, D.C., Gillette, J.R. & Brodie, B.B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185–194 (1973).
31. Cairney, D.G., Beckwith, H.K., Al-Hourani, K., Eddleston, M., Bateman, D.N. & Dear, J.W. Plasma paracetamol concentration at hospital presentation has a dose-dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Clin. Toxicol. (Phila) 54, 405–410 (2016).
32. Antoine, D.J. et al. Molecular forms of HMGB1 and Keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56, 1070–1079 (2012).
33. Antoine, D. et al. Circulating kidney injury molecule-1 predicts prognosis and poor outcome in patients with acetaminophen-induced liver injury. Hepatology 62, 591–599 (2015).
34. Sivilotti, M.L., Green, T.J., Langmann, C., Yarema, M., Juurlink, D. & Johnson, D. Multiplying the serum aminotransferase by the acetaminophen concentration to predict toxicity following overdose. Clin. Toxicol. (Phila) 48, 793–799 (2010).
35. Vliegenthart, A.D., Antoine, D.J. & Dear, J.W. Target biomarker profile for the clinical management of paracetamol overdose. Br. J. Clin. Pharmacol. 80, 351–362 (2015).
36. Thanacoody, H.K. et al. Scottish and Newcastle antiemetic pretreatment for paracetamol poisoning study (SNAP). BMC Pharmacol. Toxicol. 14, 20 (2013).
37. British National Formulary, 58th ed. (BMJ Group and RPS Publishing: London, 2009).